Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Carrington Laboratories' subsidiary DelSite Biotechnologies has signed a technology license agreement with privately held ElSohly Laboratories covering the use of GelSite polymer technology in formulating an anticancer drug. Terms of the agreement were not disclosed.
Subscribe to our email newsletter
Both DelSite Biotechnologies and ElSohly Laboratories have cooperative R&D agreements with the National Cancer Institute (NCI). Whereas DelSite’s agreement covers the development of a nasal powder vaccine for Human Papillomavirus (HPV), ElSohly’s covers an anticancer drug.
Dr Yawi Ni, senior scientist at DelSite, said “This agreement allows for the GelSite polymer to be used to stabilize and deliver a molecule smaller than we have worked with in the past. We look forward to being involved with this promising molecule and its analogs in the anticancer area. Naturally, it is exciting that our technology is now involved in two key areas of NCI research.”